Published in Molecules on August 20, 2012
Improving quantitative structure-activity relationship models using Artificial Neural Networks trained with dropout. J Comput Aided Mol Des (2016) 0.79
Perspective on computational and structural aspects of kinase discovery from IPK2014. Biochim Biophys Acta (2015) 0.75
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 6.41
Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem (1994) 3.60
FDA's policy statement for the development of new stereoisomeric drugs. Chirality (1992) 1.47
Chirality codes and molecular structure. J Chem Inf Comput Sci (2004) 1.29
Fast assignment of accurate partial atomic charges: an electronegativity equalization method that accounts for alternate resonance forms. J Chem Inf Comput Sci (2003) 1.26
3D-QSAR in drug design--a review. Curr Top Med Chem (2010) 1.24
Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening. ACS Chem Neurosci (2010) 1.16
Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci (2001) 1.15
Three-dimensional quantitative structure-activity relationships from tuned molecular quantum similarity measures: prediction of the corticosteroid-binding globulin binding affinity for a steroid family. J Chem Inf Comput Sci (1999) 1.09
Molecular quantum similarity and the fundamentals of QSAR. Acc Chem Res (2002) 0.87
Prediction of enantiomeric selectivity in chromatography. Application of conformation-dependent and conformation-independent descriptors of molecular chirality. J Mol Graph Model (2002) 0.87
E-state modeling of corticosteroids binding affinity validation of model for small data set. J Chem Inf Comput Sci (2001) 0.86
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations. J Med Chem (1997) 0.85
From Racemates to Single Enantiomers - Chiral Synthetic Drugs over the last 20 Years. Top Curr Chem (2007) 0.83
A topological account of chirality. J Chem Inf Comput Sci (2001) 0.82
Novel chirality descriptors derived from molecular topology. J Chem Inf Comput Sci (2001) 0.80
Compound analysis via graph kernels incorporating chirality. J Bioinform Comput Biol (2010) 0.80
3D-chiral atom, atom-type, and total non-stochastic and stochastic molecular linear indices and their applications to central chirality codification. J Comput Aided Mol Des (2005) 0.80
New description of molecular chirality and its application to the prediction of the preferred enantiomer in stereoselective reactions. J Chem Inf Comput Sci (2001) 0.79
Exploring enantioselective molecular recognition mechanisms with chemoinformatic techniques. J Sep Sci (2009) 0.79
Influence of chirality of amino acids on the growth of perceived taste intensity with concentration. Physiol Behav (1982) 0.78
Deriving a quantitative chirality measure from molecular similarity indices. J Med Chem (2000) 0.78
The future lies in chiral purity: a perspective. J Indian Med Assoc (2007) 0.78
Combined MEDV-GA-MLR method for QSAR of three panels of steroids, dipeptides, and COX-2 inhibitors. J Chem Inf Comput Sci (2002) 0.77
Designing chiral libraries for drug discovery. Drug Discov Today (2000) 0.77
Recent advances in chirally pure proton pump inhibitors. J Indian Med Assoc (2007) 0.76
Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science (2008) 8.04
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
New algorithms and an in silico benchmark for computational enzyme design. Protein Sci (2006) 3.40
Rosetta predictions in CASP5: successes, failures, and prospects for complete automation. Proteins (2003) 2.77
Practically useful: what the Rosetta protein modeling suite can do for you. Biochemistry (2010) 2.56
Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel. Biochemistry (2008) 2.22
RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS One (2011) 2.21
Free modeling with Rosetta in CASP6. Proteins (2005) 2.10
Interaction of a G protein with an activated receptor opens the interdomain interface in the alpha subunit. Proc Natl Acad Sci U S A (2011) 2.10
De novo high-resolution protein structure determination from sparse spin-labeling EPR data. Structure (2008) 1.84
Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science (2014) 1.81
Model-free analysis of protein backbone motion from residual dipolar couplings. J Am Chem Soc (2002) 1.65
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci (2010) 1.52
Computational methods in drug discovery. Pharmacol Rev (2013) 1.51
RosettaEPR: an integrated tool for protein structure determination from sparse EPR data. J Struct Biol (2010) 1.50
Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol (2010) 1.45
CASP6 assessment of contact prediction. Proteins (2005) 1.39
Structural models for the KCNQ1 voltage-gated potassium channel. Biochemistry (2007) 1.38
A model for the solution structure of the rod arrestin tetramer. Structure (2008) 1.37
A thorough dynamic interpretation of residual dipolar couplings in ubiquitin. J Biomol NMR (2006) 1.34
Self-consistent residual dipolar coupling based model-free analysis for the robust determination of nanosecond to microsecond protein dynamics. J Biomol NMR (2008) 1.33
EM-fold: De novo folding of alpha-helical proteins guided by intermediate-resolution electron microscopy density maps. Structure (2009) 1.32
Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies. Proteins (2009) 1.32
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology (2010) 1.30
A correspondence between solution-state dynamics of an individual protein and the sequence and conformational diversity of its family. PLoS Comput Biol (2009) 1.27
Conformation of receptor-bound visual arrestin. Proc Natl Acad Sci U S A (2012) 1.24
Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening. ACS Chem Neurosci (2010) 1.16
EM-fold: de novo atomic-detail protein structure determination from medium-resolution density maps. Structure (2012) 1.15
Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database. Molecules (2013) 1.14
Solvent accessible surface area approximations for rapid and accurate protein structure prediction. J Mol Model (2009) 1.14
Structural basis of the activity of the microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in solution. Angew Chem Int Ed Engl (2007) 1.13
Hybrid approaches: applying computational methods in cryo-electron microscopy. Curr Opin Struct Biol (2009) 1.11
The high-resolution solution structure of epothilone A bound to tubulin: an understanding of the structure-activity relationships for a powerful class of antitumor agents. Angew Chem Int Ed Engl (2003) 1.09
Side-chain orientation and hydrogen-bonding imprint supra-Tau(c) motion on the protein backbone of ubiquitin. Angew Chem Int Ed Engl (2005) 1.09
Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology (2012) 1.06
Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. J Mol Biol (2013) 1.05
Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology. Mol Pharmacol (2013) 1.05
The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. Angew Chem Int Ed Engl (2005) 1.04
Rosetta Ligand docking with flexible XML protocols. Methods Mol Biol (2012) 1.04
Algorithm for selection of optimized EPR distance restraints for de novo protein structure determination. J Struct Biol (2010) 1.02
BCL::Score--knowledge based energy potentials for ranking protein models represented by idealized secondary structure elements. PLoS One (2012) 1.01
The Kir channel immunoglobulin domain is essential for Kir1.1 (ROMK) thermodynamic stability, trafficking and gating. Channels (Austin) (2009) 1.01
The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide. Angew Chem Int Ed Engl (2006) 1.01
BCL::Fold--de novo prediction of complex and large protein topologies by assembly of secondary structure elements. PLoS One (2012) 1.00
Simultaneous prediction of protein secondary structure and transmembrane spans. Proteins (2013) 1.00
Strand-loop-strand motifs: prediction of hairpins and diverging turns in proteins. Proteins (2004) 0.98
Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS One (2013) 0.98
Computational modeling of laminin N-terminal domains using sparse distance constraints from disulfide bonds and chemical cross-linking. Proteins (2010) 0.97
Expanding the utility of NMR restraints with paramagnetic compounds: background and practical aspects. Prog Nucl Magn Reson Spectrosc (2011) 0.96
Bound to be different: neurotransmitter transporters meet their bacterial cousins. Mol Interv (2007) 0.96
A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport. J Biol Chem (2011) 0.96
Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site. Immunome Res (2007) 0.96
A structural model of the complex formed by phospholamban and the calcium pump of sarcoplasmic reticulum obtained by molecular mechanics. Chembiochem (2002) 0.96
Small-molecule ligand docking into comparative models with Rosetta. Nat Protoc (2013) 0.96
BCL::EM-Fit: rigid body fitting of atomic structures into density maps using geometric hashing and real space refinement. J Struct Biol (2011) 0.95
A unified hydrophobicity scale for multispan membrane proteins. Proteins (2009) 0.92
Characterization and modeling of the oligomeric state and ligand binding behavior of purified translocator protein 18 kDa from Rhodobacter sphaeroides. Biochemistry (2013) 0.92
Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J Clin Invest (2013) 0.92
Accessing ns-micros side chain dynamics in ubiquitin with methyl RDCs. J Biomol NMR (2009) 0.91
BCL::Align-sequence alignment and fold recognition with a custom scoring function online. Gene (2008) 0.90
Using RosettaLigand for small molecule docking into comparative models. PLoS One (2012) 0.90
Residual dipolar couplings as a tool to study molecular recognition of ubiquitin. Biochem Soc Trans (2008) 0.90
Human germline antibody gene segments encode polyspecific antibodies. PLoS Comput Biol (2013) 0.89
Design and directed evolution of a dideoxy purine nucleoside phosphorylase. Protein Eng Des Sel (2010) 0.89
Computational design of an endo-1,4-beta-xylanase ligand binding site. Protein Eng Des Sel (2011) 0.88
Ab initio protein modeling into CryoEM density maps using EM-Fold. Biopolymers (2012) 0.88
Exploring symmetry as an avenue to the computational design of large protein domains. J Am Chem Soc (2011) 0.88
BCL::MP-fold: folding membrane proteins through assembly of transmembrane helices. Structure (2013) 0.87
RosettaEPR: rotamer library for spin label structure and dynamics. PLoS One (2013) 0.87
Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. ACS Chem Neurosci (2014) 0.86
Towards ligand docking including explicit interface water molecules. PLoS One (2013) 0.86
Imino-oxy acetic acid dealkylation as evidence for an inner-sphere alcohol intermediate in the reaction catalyzed by peptidylglycine alpha-hydroxylating monooxygenase. J Am Chem Soc (2009) 0.86
Computational design of protein-ligand interfaces: potential in therapeutic development. Trends Biotechnol (2011) 0.85
Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12. Mol Pharmacol (2012) 0.85
A physical model for PDZ-domain/peptide interactions. J Mol Model (2010) 0.85
Measurement of aptamer-protein interactions with back-scattering interferometry. Anal Chem (2011) 0.85
An allosteric mechanism for drug block of the human cardiac potassium channel KCNQ1. Mol Pharmacol (2012) 0.84
Assessment and challenges of ligand docking into comparative models of G-protein coupled receptors. PLoS One (2013) 0.84
Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand. Chem Biol Drug Des (2012) 0.84
Potential of fragment recombination for rational design of proteins. J Am Chem Soc (2012) 0.83
Octarellin VI: using rosetta to design a putative artificial (β/α)8 protein. PLoS One (2013) 0.82
Unique gating properties of C. elegans ClC anion channel splice variants are determined by altered CBS domain conformation and the R-helix linker. Channels (Austin) (2010) 0.81
Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. J Mol Model (2012) 0.80
BCL::Fold--protein topology determination from limited NMR restraints. Proteins (2013) 0.80
CASP10-BCL::Fold efficiently samples topologies of large proteins. Proteins (2015) 0.80
Iterative Molecular Dynamics-Rosetta Protein Structure Refinement Protocol to Improve Model Quality. J Chem Theory Comput (2013) 0.79
Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest (2015) 0.79
Thiorphan, tiopronin, and related analogs as substrates and inhibitors of peptidylglycine alpha-amidating monooxygenase (PAM). FEBS Lett (2005) 0.79
Membrane protein structure determination using paramagnetic tags. Structure (2011) 0.79
Evidence for substrate preorganization in the peptidylglycine α-amidating monooxygenase reaction describing the contribution of ground state structure to hydrogen tunneling. J Am Chem Soc (2010) 0.79
Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporter. ACS Chem Neurosci (2010) 0.79
The evolutionarily conserved residue A653 plays a key role in HERG channel closing. J Physiol (2009) 0.78
Design of native-like proteins through an exposure-dependent environment potential. Biochemistry (2011) 0.78
Pancreatic polypeptide is recognized by two hydrophobic domains of the human Y4 receptor binding pocket. J Biol Chem (2013) 0.78